WHITE PAPER
A Practical Approach and Lessons Learned from Aligning Regulatory Master and Reference Data with SPOR Executive Summary
Jan 03, 2023
Download

Jens-Olaf Vanggaard and Gary Wilson discuss the implications of SPOR for biopharmaceutical companies operating in the EU and steps that companies can take to accelerate alignment and compliance with the new guidance, including the use of SPORIFY.

Related solutions

Contact Us